CORT | Jotup

Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on:

Tuesday, February 8, 2022

NASDAQ, Liver disease, Corcept Therapeutics, GLOBE, Investor, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Weight gain, Ovarian cancer, Food, CORT, Patient, Pharmaceutical industry

Key Points:

MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022.
The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call.
Corcepts approved medication, Korlym, was the first drug approved by the U.S. Food and Drug Administration for patients with Cushings syndrome.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Agrify, Affirm Holdings, and Medallion Financial and Encourages Investors to Contact the Firm

Retrieved on:

Monday, February 7, 2022

Key Points:

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
For more information on the Medallion Financial investigation go to: https://bespc.com/cases/MFIN
About Bragar Eagel & Squire, P.C.
The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDX, Medallion, and Corcept and Encourages Investors to Contact the Firm

Retrieved on:

Tuesday, February 1, 2022

Key Points:

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
On this news, Agrifys common stock price fell sharply during intraday trading on December 16, 2021.
For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
About Bragar Eagel & Squire, P.C.
The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Cronos, Everbridge, and Hollysys and Encourages Investors to Contact the Firm

Retrieved on:

Thursday, January 27, 2022

Key Points:

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.
For more information on the Hollysys investigation go to: https://bespc.com/cases/HOLI
About Bragar Eagel & Squire, P.C.
The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)

Retrieved on:

Tuesday, January 25, 2022

Legal, Professional Services, Lists of diseases, Therapy, News, USAO, Record, Accountability Act, NASDAQ, Company, Corcept Therapeutics, District, Sale, HIPPA, Health Insurance Portability and Accountability Act, CORT, Pharmaceutical industry, Medical device

Key Points:

Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the securities laws.
Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders.
If you would like more information about Corcept Therapeutics Incorporated's misconduct, click here .
If you own shares of Corcept Therapeutics Incorporated, contact us to learn more about your rights.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT

Retrieved on:

Sunday, January 23, 2022

U.S. Securities and Exchange Commission, Corcept Therapeutics, Accountability Act, News, Health Insurance Portability and Accountability Act, CORT, Pomerantz, Record, NASDAQ, Company, LLP, GLOBE, HIPAA, District, Sale, Private investigator

Key Points:

NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ:CORT).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Is Investigating Natera, Nuvei, Corcept Therapeutics, and Agrify and Encourages Investors to Contact the Firm

Retrieved on:

Saturday, January 22, 2022

Key Points:

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
On this news, Nateras stock declined as much as 3.5% during intraday trading on January 3, 2022, thereby injuring investors.
For more information on the Agrify investigation go to: https://bespc.com/cases/AGFY
About Bragar Eagel & Squire, P.C.
The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Tecnoglass, Everbridge, Corcept, and Agrify and Encourages Investors to Contact the Firm

Retrieved on:

Monday, January 17, 2022

Key Points:

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
On December 9, 2021, Hindenburg Research published a short-seller report on Tecnoglass, Cocaine Cartel Connections, Undisclosed Family Deals, And Accounting Irregularities All In One Nasdaq SPAC.
For more information on the Agrify investigation go to: https://bespc.com/cases/AGFY
About Bragar Eagel & Squire, P.C.
The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT

Retrieved on:

Thursday, January 13, 2022

Key Points:

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ:CORT).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Agrify, Affirm Holdings, and Medallion Financial and Encourages Investors to Contact the Firm

Retrieved on:

Wednesday, January 12, 2022

Key Points:

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
For more information on the Medallion Financial investigation go to: https://bespc.com/cases/MFIN
About Bragar Eagel & Squire, P.C.
The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.